Preclinical effect of absorption modifying excipients on rat intestinal

Subscriber access provided by GRIFFITH UNIVERSITY

Article

Preclinical effect of absorption modifying excipients on rat intestinal transport of five model compounds and the intestinal barrier marker Cr-EDTA 51

David Dahlgren, Carl Roos, Anders Lundqvist, Peter Langguth, Christer Tannergren, Markus Sjöblom, E. Sjögren, and H. Lennernas Mol. Pharmaceutics, Just Accepted Manuscript • DOI: 10.1021/acs.molpharmaceut.7b00353 • Publication Date (Web): 24 Jul 2017 Downloaded from http://pubs.acs.org on July 25, 2017

Just Accepted “Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a free service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are accessible to all readers and citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.

Molecular Pharmaceutics is published by the American Chemical Society. 1155 Sixteenth Street N.W., Washington, DC 20036 Published by American Chemical Society. Copyright © American Chemical Society. However, no copyright claim is made to original U.S. Government works, or works produced by employees of any Commonwealth realm Crown government in the course of their duties.

Page 1 of 29

Molecular Pharmaceutics Dahlgren, D

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Absorption Modifiers

1 (25)

1

Preclinical effect of absorption modifying

2

excipients on rat intestinal transport of model

3

compounds and the mucosal barrier marker

4

51

Cr-EDTA

5

Dahlgren, David1; Roos, Carl1; Lundqvist, Anders2; Tannergren, Christer2; Langguth, Peter3; Sjöblom,

6

Markus4; Sjögren, Erik1; Lennernäs, Hans1*

7

1

Department of Pharmacy, Uppsala University, Uppsala, Sweden

8

2

AstraZeneca R&D, Gothenburg, Sweden

9

3

School of Pharmacy, Johannes Gutenberg-University, Mainz, Germany

10

4

Department of Neuroscience, Division of Physiology, Uppsala University, Uppsala, Sweden

11 12

*Address correspondence to:

13

Hans Lennernäs, PhD

14

Professor in Biopharmaceutics

15

Department of Pharmacy

16

Uppsala University

17

Box 580

18

SE-751 23 Uppsala, Sweden

19

Email: [email protected]

20

Phone: +46 – 18 471 4317

21

Fax: +46 – 18 471 4223

22 23 24

ACS Paragon Plus Environment


1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Page 2 of 29


2 (25)

25

Abstract

26

There is a renewed interest from the pharmaceutical field to develop oral formulations of compounds

27

such as peptides, oligonucleotides, and polar drugs. However, these often suffer from insufficient

28

absorption across the intestinal mucosal barrier. One approach to circumvent this problem is the use of

29

absorption modifying excipient(s) (AME). This study determined the absorption enhancing effect of

30

four AMEs (sodium dodecyl sulfate, caprate, chitosan, N-acetylcysteine) on five model compounds in

31

a rat jejunal perfusion model. The aim was to correlate the model compound absorption to the blood-

32

to-lumen clearance of the mucosal marker for barrier integrity, 51Cr-EDTA. Sodium dodecyl sulfate

33

and chitosan increased the absorption of the low permeation compounds but had no effect on the high

34

permeation compound, ketoprofen. Caprate and N-acetylcysteine did not affect the absorption of any

35

of the model compounds. The increase in absorption of the model compounds was highly correlated to

36

an increased blood-to-lumen clearance of

37

could be used as a general, sensitive, and validated marker molecule for absorption enhancement when

38

developing novel formulations.

51

Cr-EDTA, independent of the AME. Thus,

51

Cr-EDTA

39 40

………

41

Keywords: absorption modifiers, permeation enhancers, intestinal perfusion, bioequivalence,

42

pharmaceutical development.

43 44

Abbreviations: AME – absorption modifying excipient, CL – clearance, IEC - intestinal epithelial

45

cells, NAC - N-acetylcysteine, SDS – sodium dodecyl sulfate,


Page 3 of 29


1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


3 (25)

46

Introduction

47

There is a renewed interest from the pharmaceutical field to develop oral formulations of drugs with

48

low intestinal membrane permeability, such as peptides, oligonucleotides, and polar drugs (polar

49

surface area >100Å2) with a molecular mass between 250-1200 g/mol.1 For drug molecules to be

50

absorbed following oral administration, they have to cross the single layer of columnar intestinal

51

epithelial cells (IECs). These IECs form a semi-permeable mucosal barrier that is under strict

52

physiological regulation by inflammatory factors and luminal content.2 The IECs, together with a thin

53

mucus layer, form a barrier that restricts translocation of large, luminal constituents, such as proteins

54

and bacteria, while allowing a rapid and high uptake of nutrients, water, electrolytes, and some

55

xenobiotics (including drugs and antioxidants).3 Oral formulations with absorption modifying

56

excipients(s) (AME) affect the IEC barrier integrity to increase transport of dissolved drug from the

57

intestinal lumen to the blood. AMEs can be used alone or in combination to increase drug uptake in at

58

least four ways. The AME can: i) adhere to the IEC and/or mucus to increase drug concentration at the

59

mucosal membrane; ii) degrade the intestinal mucus to increase contact between the IEC and drug; iii)

60

increase drug permeation by altering the integrity of the IEC lipid bilayer; and iv) increase drug

61

permeation by altering the paracellular tight junction complexes between IECs.4,5 The use of AMEs

62

has not reached clinical breakthrough, but there are several formulations in various stages of clinical

63

development.4

64 65

However, there are several unresolved issues related to the development and use of AME in oral

66

pharmaceutical products. The safety of AMEs are a major concern for patients, pharmaceutical

67

companies, and regulatory agencies, and consequently most novel formulation strategies are based on

68

AMEs shown to be safe in humans.1 For instance, luminal pH, osmolarity, bile acids, nutrients, and

69

microbiota, are all shown to induce various physiological responses affecting the function of the

70

epithelial barrier.6-8 An alteration of the mucosal barrier function facilitating epithelial permeation of

71

drugs might also increase translocation of harmful entities, such as toxins, bacteria, and viruses.

72

Further, many pharmaceutical excipients with a suspected absorption enhancing effect are also used in



1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


Page 4 of 29 4 (25)

73

oral enabling formulations, e.g., surfactants as a wetting/solubilizing agent.9 Whether these excipients

74

affect the bioequivalence (BE) of drug products – or drug product-drug interactions – is another

75

important issue.10

76 77

To enable early and more reliable assessment of AMEs, their effects in pre-clinical models need to be

78

better understood. The promising effects in in vitro (e.g. Caco-2 and/or excised intestinal segments in

79

Ussing models) as well as in animal models (e.g. rat intestinal perfusion) are notoriously difficult to

80

replicate in humans. Often they do not take into account the designed formulation features, such as

81

release, effects of local solubilization, and co-exposure of AME(s) and drug to the mucus and/or

82

epithelial barrier.1,11

83 84

The main objective of this study was to improve the mechanistic understanding of four commonly

85

used AMEs on the small intestinal absorption of model compounds (atenolol, acyclovir, enalaprilat,

86

ketoprofen, and phenol red). The rat was used as model animal as it is shown to be most accurate in

87

predicting human intestinal absorption.12-14 The model compounds were single-pass perfused in a

88

segment of the rat jejunum, with an intact blood supply, as a cocktail solution in two consecutive 75

89

min periods. The first period was the control (no AME) and the second period contained one of the

90

following AME: sodium dodecyl sulfate (SDS), sodium caprate, chitosan, N-acetylcysteine (NAC),

91

and chitosan+NAC (ChNAC). The AMEs were tested at two concentrations. A second important

92

objective was to study the effect of the AME on the blood-to-lumen clearance (CL) of a common

93

biologically inert marker for mucosal integrity, 51Cr-EDTA, which is transported across the rat IEC by

94

the paracellular route when intravenously administered.15 An increased intestinal CL of 51Cr-EDTA is

95

highly correlated with an altered IEC barrier function in both animal and human experiments.16,17

96


Page 5 of 29


1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


5 (25)

97

Methods

98

Active pharmaceutical ingredients, pharmaceutical excipients and other chemicals

99

Six model compounds were selected: acyclovir, atenolol, enalaprilat, ketoprofen, phenol red, and

100

metoprolol. All metoprolol plasma samples were below the lower limit of quantification in the

101

analytical assay and therefore no results for metoprolol were obtained. The model compounds belong

102

to classes II and III according to the biopharmaceutics classification system (BCS).18 BCS class and

103

physicochemical properties are summarized in Table 1. The four AMEs were: SDS (an anionic

104

surfactant), sodium caprate (a fatty acid), chitosan (a polysaccharide), and NAC (a mucolytic

105

agent)(Table 2). Atenolol and metoprolol tartrate were provided by AstraZeneca AB (Mölndal,

106

Sweden). Acyclovir, enalaprilat, ketoprofen, phenol red, sodium caprate, sodium dodecyl sulfate

107

(SDS), N-acetyl-L-cysteine (NAC), bovine albumin (A2153), and Inactin were purchased from Sigma-

108

Aldrich (St. Louis, MO, US). Sodium phosphate dibasic dihydrate (Na2HPO4·2H2O), potassium

109

dihydrogen phosphate (KH2PO4), sodium hydroxide (NaOH), and sodium chloride (NaCl) were

110

purchased

111

ethylenediaminetetraacetate (51Cr-EDTA) was purchased from PerkinElmer Life Sciences (Boston,

112

MA). Chitosan hydrochloride (molecular mass 40-300 kDa, degree of acetylation 8.8%) was

113

purchased from Kraeber & Co GmbH (Ellerbek, Germany).

from

Merck

KGaA

(Darmstadt,

Germany).

51

Chromium-labeled

114 115

Study solutions

116

The intravenous (iv) cassette solution (312.5 µM) was prepared by dissolving all of the model

117

compounds in 100 mL saline and adjusting pH to 6.5 (0.1 M NaOH solution).

118 119

Ten perfusion solutions were prepared, all containing 50 µM of all model compounds. One contained

120

no AME (control) and nine test solutions contained AME. Eight test solutions contained one of the

121

following AME (w/v): SDS 0.1% (3.5 mM), SDS 0.5% (17.3 mM), caprate 0.04% (2.1 mM), caprate

122

0.2% (10.3 mM), chitosan 0.1%, chitosan 0.5%, NAC 0.1% (6.1 mM), and NAC 0.5% (30.6 mM).

123

One test solution contained NAC (30.6 mM) and chitosan (ChNAC), at 0.5% w/v each. The highest



1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


Page 6 of 29 6 (25)

124

concentration of AME was always below a clinically acceptable dose to swallow (1 g), according to

125

the BCS (dissolved in 250 mL water). The two caprate concentrations (2.1 and 10.3 mM) were both

126

below the reported critical micelle concentration (CMC) of caprate in saline (25 mM).19 The highest

127

caprate concentration was chosen to be below its solubility limit at pH 6.5.20 For SDS, one solution

128

(3.5 mM) was close to the reported CMC (between 2-6 mM depending on salt concentration) and one

129

above (17.3 mM).21,22

130 131

Each perfusion solution (100 mL) was prepared on the day of experiment by mixing 16 mL of a 312.5

132

µM stock solution containing a cocktail of all model compounds and one of the AME (pre-dissolved in

133

water at a concentration of 1g/100 mL), yielding the wanted concentrations mentioned above. Stock

134

solutions (67 mM) of Na2HPO4 and KH2PO4 were added at volumes giving a final pH of 6.5 at a

135

phosphate concentration of 5-8 mM. The solutions containing chitosan and NAC required addition of

136

1 M NaOH to obtain a final pH of 6.5. Deionized water was added to a final volume of 100 mL and

137

isotonicity (290 mOsm) was adjusted using NaCl. No incompatibility or degradation of the study

138

compounds in solution (pH 6.5, 37 °C) was observed during 4 h.

139 140

Animals and study design

141

The study was approved by the local ethics committee for animal research (no: C64/16) in Uppsala,

142

Sweden. Male Wistar Han rats (strain 273) from Charles River (Germany) weight 300-440 g were

143

used. The animals arrived at the animal lab facility at least one week before the experiment and were

144

allowed water and food ad libitum during this period. Housing conditions were 12:12 h light-dark

145

cycle and 21-22 °C. On the study day, the rats were anesthetized using an intraperitoneal injection of a

146

10% w/v Inactin solution (160 mg/kg) then laid down on a pre-warmed heating pad. Body temperature

147

was maintained at 37.5 ± 0.5°C by means of an IR-lamp and a temperature regulator controlling the

148

heating pad. A cannula was inserted into the trachea to ensure a free airway. The femoral vein and

149

artery were thereafter cannulated with PE-50 polyethylene catheters (Becton, Dickinson, Franklin

150

Lakes, NJ). For continuous recordings of the systemic arterial blood pressure (BP), the arterial catheter


Page 7 of 29


1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


7 (25)

151

containing 20 IU/ml heparin isotonic saline was connected to a transducer operating a PowerLab

152

system (AD Instruments, Hastings, UK), in order validate the condition of the animal.

153 154

At the iv administration, 1 mL of the 312.5 µM stock solution containing the model compounds was

155

bolus administered through the femoral vein (dose: acyclovir 70 µg, atenolol 83 µg, enalaprilat 109

156

µg, ketoprofen 80 µg, metoprolol 83 µg, and phenol red 111 µg) followed by a 0.5 mL saline flush to

157

ensure complete administration of the doses.

158 159

The single- pass perfusion experiment in rat was performed as follows. The abdomen was opened with

160

a 3-5 cm longitudinal incision along the midline. A jejunal segment of 9-14 cm, approximately 5 cm

161

distal to the ligament of Treitz, was located and cannulated with a silicone tube (Silastic, 1.0 mm ID

162

Dow Corning, Midland, MI). The chosen segment was placed on the abdomen of the rat to avoid

163

intestinal folding and to visually check intestinal motor activity during the experiment. The intestine

164

was covered with Saran wrap to maintain body temperature and to avoid fluid loss. The bile duct was

165

cannulated with a PE-10 polyethylene tube close to its entrance into the duodenum (2-3 mm) to avoid

166

pancreaticobiliary secretion into the duodenum. After completion of surgery,

167

administered iv as a bolus of 75 µCi (0.4 mL) followed by a continuous infusion at a rate of 50 µCi

168

per hour (1 ml/h) for the duration of the experiment. Each intestinal segment was single-passed

169

perfused at 0.2 ml/min (peristaltic pump, Gilson Minipuls 3, Le Bel, France) with 37° C, phosphate

170

buffered saline (6 mM, pH 6.5), during the first 30 minutes following surgery. This was to allow

171

cardiovascular, respiratory, and intestinal functions to stabilize, and to achieve stable

172

activity in blood plasma. The length of the intestinal segment was measured after the jejunal

173

cannulation and the weight of the segment was measured after the experiment.

51

Cr-EDTA was

51

Cr-EDTA

174 175

Following the equilibration, each experiment was divided into two parts: i) in the first part, the

176

segment was perfused with the control solution (containing model compounds but no AME) for 75

177

min; ii) this was directly followed by a 75 min perfusion of a solution containing one of the nine AME

178

containing test solutions (containing model compounds and AME). In one experiment the same



1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Page 8 of 29


8 (25)

179

control solution was perfused during both 75 min periods to evaluate possible time-dependent effects

180

on compound flux. The experimental design enabled each rat to serve as its own control. Each

181

experiment was started with a rapid filling of the whole segment with the solution being perfused. The

182

intestinal segment and perfusion solutions were kept at 37 °C and all outgoing perfusate was collected

183

quantitatively at 15 min intervals, giving five samples during each of the two consecutive 75 min

184

perfusion periods, for a total of 10 samples.

185 186

Blood samples of

Preclinical effect of absorption modifying excipients on rat intestinal

Recommend Documents